Ziconotide

Drug Profile

Ziconotide

Alternative Names: CI 1009; MVIIA; Prialt; SNX 111; SNX 194

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Elan Pharmaceuticals
  • Class Conotoxins; Neuroprotectants; Non-opioid analgesics; Peptides
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pain
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pain
  • Discontinued Craniocerebral trauma; Stroke

Most Recent Events

  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 18 Jan 2012 Azur Pharma has merged with Jazz Pharmaceuticals Inc to form Jazz Pharmaceuticals plc
  • 30 Jan 2007 Discontinued - Phase-III for Head injuries in European Union (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top